Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics


Pacira BioSciences, Inc. (PCRX): $57.19

-1.11 (-1.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCRX POWR Grades


  • PCRX scores best on the Growth dimension, with a Growth rank ahead of 96.89% of US stocks.
  • The strongest trend for PCRX is in Growth, which has been heading up over the past 179 days.
  • PCRX ranks lowest in Momentum; there it ranks in the 8th percentile.

PCRX Stock Summary

  • PCRX's current price/earnings ratio is 81.38, which is higher than 91.31% of US stocks with positive earnings.
  • With a year-over-year growth in debt of 108.61%, Pacira BioSciences Inc's debt growth rate surpasses 90.46% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Pacira BioSciences Inc is reporting a growth rate of 92.64%; that's higher than 79.07% of US stocks.
  • Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are ICHR, INPX, XL, ONTF, and RGEN.
  • PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.

PCRX Valuation Summary

  • In comparison to the median Healthcare stock, PCRX's price/earnings ratio is 58.63% lower, now standing at 15.1.
  • Over the past 129 months, PCRX's price/sales ratio has gone down 2.9.
  • Over the past 129 months, PCRX's EV/EBIT ratio has gone up 41.4.

Below are key valuation metrics over time for PCRX.

Stock Date P/S P/B P/E EV/EBIT
PCRX 2021-08-31 5.2 3.8 15.1 36.1
PCRX 2021-08-30 5.2 3.8 15.1 35.9
PCRX 2021-08-27 5.2 3.8 15.2 36.1
PCRX 2021-08-26 5.1 3.7 14.7 35.1
PCRX 2021-08-25 5.2 3.8 15.1 35.9
PCRX 2021-08-24 5.2 3.8 14.9 35.6

PCRX Growth Metrics

    The 4 year price growth rate now stands at -16.16%.
  • Its 4 year net income to common stockholders growth rate is now at 97.36%.
  • Its 5 year cash and equivalents growth rate is now at 55.84%.
Over the past 34 months, PCRX's revenue has gone up $187,551,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 541.533 125.717 41.98
2021-09-30 513.313 149.169 61.625
2021-06-30 503.075 128.663 174.084
2021-03-31 442.99 82.905 147.734
2020-12-31 429.647 77.032 145.523
2020-09-30 421.097 56.269 126.121

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
  • PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
  • BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.394 0.738 0.064
2021-03-31 0.381 0.731 0.042
2020-12-31 0.411 0.727 0.042
2020-09-30 0.451 0.729 0.029
2020-06-30 0.491 0.740 0.018
2020-03-31 0.536 0.749 0.030

PCRX Price Target

For more insight on analysts targets of PCRX, see our PCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.00 Average Broker Recommendation 1.5 (Moderate Buy)

PCRX Stock Price Chart Interactive Chart >

Price chart for PCRX

PCRX Price/Volume Stats

Current price $57.19 52-week high $82.16
Prev. close $58.30 52-week low $45.05
Day low $57.06 Volume 48,315
Day high $58.40 Avg. volume 520,708
50-day MA $62.50 Dividend yield N/A
200-day MA $62.03 Market Cap 2.60B

Pacira BioSciences, Inc. (PCRX) Company Bio


Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.


PCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCRX Latest Social Stream


Loading social stream, please wait...

View Full PCRX Social Stream

Latest PCRX News From Around the Web

Below are the latest news stories about Pacira BioSciences Inc that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

Yahoo | February 25, 2022

Pacira BioSciences Non-GAAP EPS of $0.97 beats by $0.14, revenue of $159.19M beats by $1.77M

Pacira BioSciences press release (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.97 beats by $0.14. Revenue of $159.19M (+21.5% Y/Y) beats by $1.77M. “The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in a pivotal year for Pacira, allowing us to enter 2022 in the strongest financial position in our...

Seeking Alpha | February 24, 2022

Pacira BioSciences, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Pacira BioSciences, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 —— Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million —— More than 10 million patients have received EXPAREL since launch —— Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial re

Yahoo | February 24, 2022

Read More 'PCRX' Stories Here

PCRX Price Returns

1-mo -9.87%
3-mo -26.58%
6-mo -4.95%
1-year -4.65%
3-year 34.44%
5-year 19.90%
YTD -4.95%
2021 0.55%
2020 32.10%
2019 5.30%
2018 -5.76%
2017 41.33%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5159 seconds.